Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoroscopically guided intra-articular triamcinolone injection for sacroiliac joint pain
IRCT20200217046523N4Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triamcinolone in sacroiliac joint disruption (SIJD), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Back pain at 6 months. Started Nov 2020; status: completed.
02
Drugs
triamcinolone
03
Conditions
sacroiliac joint disruption (SIJD)
Beyond the preview
Go deeper on IRCT20200217046523N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046523N4.